Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense
Disclosed deals
Every published round Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense took part in, and every
parcel of existing shares it bought off another holder. Deals we hold
but haven't published yet are not counted.
Companies Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense has backed in a published round, and
companies whose existing shares it bought off another holder.
Fund closes reported for
Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, as distinct from the investments it has made.
No fund closes recorded for Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense yet.
Portfolio companies acquired
Companies Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense has backed that another company then
bought. An exit for the holding, not a deal Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense did.
Stories naming Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense. Where several outlets covered the
same round, they are bundled under whichever ran the fullest account.
Melbourne's ENA Respiratory has won a further US$3.18 million US Defense Department contract to widen its INNA-051 Phase Ib trial to younger adults, extending the US$8.18 million the agency had already committed.